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Abstract
Mesenchymal stromal cells (MSCs) reside in many organs including lung, as shown by their isolation from fetal lung tissues,
bronchial stromal compartment, bronchial-alveolar lavage and transplanted lung tissues. It is still controversial whether lung
MSCs can undergo mesenchymal-to-epithelial-transition (MET) and possess immune regulatory properties. To this aim, we
isolated, expanded and characterized MSCs from normal adult human lung (lung-hMSCs) and compared with human bone
marrow-derived MSCs (BM-hMSCs). Our results show that lung-MSCs reside at the perivascular level and do not significantly
differ from BM-hMSCs in terms of immunophenotype, stemness gene profile, mesodermal differentiation potential and
modulation of T, B and NK cells. However, lung-hMSCs express higher basal level of the stemness-related marker nestin and
show, following in vitro treatment with retinoic acid, higher epithelial cell polarization, which is anyway partial when
compared to a control epithelial bronchial cell line. Although these results question the real capability of acquiring epithelial
functions by MSCs and the feasibility of MSC-based therapeutic approaches to regenerate damaged lung tissues, the
characterization of this lung-hMSC population may be useful to study the involvement of stromal cell compartment in lung
diseases in which MET plays a role, such as in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
Citation: Ricciardi M, Malpeli G, Bifari F, Bassi G, Pacelli L, et al. (2012) Comparison of Epithelial Differentiation and Immune Regulatory Properties of Mesenchymal
Stromal Cells Derived from Human Lung and Bone Marrow. PLoS ONE 7(5): e35639. doi:10.1371/journal.pone.0035639
Editor: Marco Idzko, University Hospital Freiburg, Germany
Received January 13, 2012; Accepted March 19, 2012; Published May 2, 2012
Copyright:  2012 Ricciardi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the grant ‘‘Ricerca Sanitaria Finalizzata per l’anno 2009’’ from ‘‘Regione del Veneto’’, and by the Italian Ministry of
University and Scientific Research (PRIN 2007) and Fondazione CARIVERONA, Bando 2008. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mauro.krampera@univr.it
Introduction
Mesenchymal stromal cells (MSCs) are multipotent progenitor
cells firstly isolated from human bone marrow (BM-hMSCs),
displaying differentiation potential into adipocytes, osteoblasts,
condrocytes and other tissues of mesodermal origin [1,2], and
specific immune regulatory properties [3,4]. BM-hMSCs derive
from single-cell suspensions by the selective growth of plastic-
adherent fibroblast-like cell colonies in liquid culture medium [2].
The easy accessibility of BM-hMSCs, together with their multi-
lineage differentiation potential, raised the hope that these cells
could be used for the regeneration of damaged tissues of different
origin, including epithelial tissues such as lung. Different reports
suggested that BM-hMSCs may differentiate in vitro and in vivo into
epithelial cells [5,6] through a limited and not fully characterized
process called mesenchymal-to-epithelial-transition (MET) [7–9].
However, the attempts to induce epithelial phenotype by specific
signals, the characterization of the epithelial cells derived from in
vitro MET and the transplantation of BM-hMSCs in vivo into
injured lungs led to quite controversial results [10].
MSCs exist in organs other than BM at perivascular level [11],
and the tissue origin of MSCs may be responsible for some specific
differentiation patterns [12]. The presence of MSCs in human
lung has been suggested indirectly by their isolation from fetal lung
tissues [13] and bronchioalveolar lavage (BAL) obtained from lung
transplanted recipients [14], and by the evidence that the
pulmonary stromal compartment possess multilineage differenti-
ation properties [15]. However, lung-derived MSCs (lung-hMSCs)
still lack extensive characterization and no data are available about
their origin, tissue location, MET capability and immune
regulatory properties towards T, B and NK cells.
Aim of this work was to identify, isolate, expand and
characterize lung-hMSCs by comparing their features with those
already described in BM-hMSCs. In addition, different media
containing epithelial differentiation inducers were tested in vitro to
verify whether lung-hMSCs were more prone than BM-MSCs to
acquire specific epithelial tissue-related properties. In particular,
retinoic acid (RA) was employed because its involvement in
normal lung development [16]; in fact, the disruption of RA
signaling leads to major abnormalities in the embryo, including
abnormal lung morphogenesis, altered development of the
tracheal and bronchopulmonary structures, abnormal differentia-
tion of the respiratory epithelium [17,18], and lung agenesis
[19,20]. Moreover, it has been recently shown that RA, when
administered to adult animals, triggers some genes normally active
during lung development, thus ameliorating both functions and
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molecular inducers of cell differentiation in many organs and
may influence the expression of intermediate filaments such as
keratins in different cell types [24–26], including MSCs and
embryonic stem cells [27,28]; in addition, RA can reduce the
fibrosis occurring after lung injury by down-regulating cytokine
secretion and directly inhibiting the proliferation of fibroblasts
[29,30].
Materials and Methods
MSC Characterization
BM-hMSCs were obtained from BM aspirates of healthy
donors, after written informed consent, as approved by the Ethics
Committee of Azienda Ospedaliera Universitaria Integrata
Verona (N. Prog. 1828, May 12, 2010 - ‘Institution of cell and tissue
collection for biomedical research in Onco-Hematology’). BM mononuclear
cells were separated by density gradient centrifugation and
cultured in 25 cm
2 flasks (BD Biosciences) in 5 ml of culture
medium (Dulbecco’s modified Eagle medium (DMEM), 18% fetal
bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml strepto-
mycin). Lung-hMSCs were collected from lung explants obtained
from living organ donors and not employed for transplantation,
according to the Italian legislation concerning organ explantation
and under approval of the Ethics Committee of Azienda
Ospedaliera Universitaria Integrata Verona (N. Prog. 1899,
December 22, 2010 - ‘Institution of pulmonary tissue collection for
biomedical research in Oncology and regenerative medicine’). Human lung
tissues were shipped to the laboratory on ice within 12 hours from
explantation and then immediately fractionated, enzymatically
digested with collagenase and dissociated using gentleMACS
TM
Dissociator (Miltenyi). At the end of the procedure the single-cell
suspension was filtered with a cell strainer, and mononuclear cells
were collected by centrifugation and cultured in 25 cm
2 flasks (BD
Biosciences) in the same culture medium used for BM-hMSC
expansion. BM- and lung-hMSC cultures were incubated at 37uC
in a 5% CO2 atmosphere. After 72 hours, non-adherent cells were
removed. When 70–80% confluent, adherent cells were washed
with phosphate-buffered saline (PBS), trypsinized, harvested, and
expanded in larger flasks.
Immunophenotyping of hMSCs was carried out by using
monoclonal antibodies (mAbs) specific for CD105, CD106, CD73,
CD44 and CD90. In addition, the lack of hematopoietic and
endothelial markers (CD31, CD34, CD14, CD45) was assessed.
Further characterization of hMSCs was obtained with monoclonal
antibodies specific for CD80, CD86, HLA-class I and II, CD117,
NG2, Nestin, CD146. All antibodies were purchased from
Pharmingen/Becton Dickinson (Milan, Italy). For immunopheno-
typic analysis, cultured cells were detached by using trypsin/
ethylendiaminetetraacetic acid (EDTA), washed with PBS and
resuspended at 10
6 cells/ml. Cell suspension was incubated with
specific antibody at room temperature (RT) for 15 minutes.
Additional steps with Cytofix/Cytoperm (BD Biosciences) were
performed if required, in accordance with supplier’s instructions.
Unconjugated mouse IgG1-PE, IgG2-PE and IgG1 + Goat anti-
Mouse-PE (all BD Biosciences) were used as relative control
isotypes. At least 10,000 events were analyzed by flow cytometry
(FACScalibur; Becton Dickinson, Milan, Italy) and Cell Quest
Software.
MSC differentiation potential was assessed by testing their
ability to differentiate into adipocytes, osteoblasts and chondro-
cytes in presence of specific differentiation media [31]. Adipocytic
differentiation was achieved after 3 week-culture of MSCs with
adipogenic medium (AM), containing 10
26 M dexamethasone,
10 mg/ml insulin and 100 mg/ml 3-isobutyl-1-Methylxantine.
Osteoblastic differentiation was achieved after 2 week-culture
with osteoblastic medium (OM) containing 10
27 M dexametha-
sone, 50 mg/ml ascorbic acid and 10 mM m-glycerophosphate.
Chondrocytic differentiation was achieved after 2 week-culture
with chondrocytic medium (CM), containing 10
27 M dexameth-
asone and 10 ng/ml TGF-b (SIGMA), which was added to a
pellet of 2.5610
5 MSCs centrifuged at 1500 rpm for 10 minutes.
Oil-red-O, von Kossa and toluidine blue dyes were employed to
identify adipocytes, osteoblasts and chondrocytes, respectively.
To assess population doubling time, Lung-hMSCs were plated
at 5610
4 concentration in duplicate in DMEM at different
passages (P3, P5 and P7). Cells were detached and counted after
24, 48 and 72 hours. Data were analyzed by using the formula
described at http://www.doubling-time.com/compute.php web-
site to generate exponential regression based on Least Squares
Fitting-Exponential.
To perform colony forming unit assay-fibroblast (CFU-F) and
self-renewal assay, hMSCs were plated at 4, 20 and 40 cells/cm
2
concentrations. After 14 days of culture, every single cell-derived
cluster with more than 50 cells was considered as colony. CFU-F
assay was performed at passage P2, P3, P4, P5 and P6. CFU-F
colonies were stained with May-Grunwald Giemsa and then
counted. Self-renewal assay was performed by replating primary
colonies and verifying that these cells were capable of forming
secondary colonies.
For immune regulation assays, human peripheral blood
mononuclear cells were obtained from healthy blood donors after
written informed consent, as approved by the Ethics Committee of
Azienda Ospedaliera Universitaria Integrata Verona (N. Prog.
1828, May 12, 2010 - ‘Institution of cell and tissue collection for biomedical
research in Onco-Hematology’); human B, NK and T cells were
selected by using negative immunomagnetic selection kits
(Miltenyi Biotec, Calderara di Reno (BO), Italy). Cell purity was
evaluated by using specific monoclonal antibodies and flow
cytometry; only samples with purity .95% were used. Prolifer-
ation of stimulated B, NK and T cells in coculture with BM- and
lung-hMSCs was evaluated at day 4 (B and NK cells) and at day 7
(T cells) by means of CFDA-SE dilution method (Invitrogen). All
effectors were labelled with CFDA-SE [5 mM] and then cocul-
tured with hMSCs. At the end of the coculture, lymphocytes were
stained with anti-CD45 mAb (Beckton Dickinson, Milan Italy) and
Topro3 (Invitrogen) and analyzed. B cells were cocultured in
RPMI + 10% FBS (Gibco) and stimulated with CD40 ligand and
its enhancer MAB050 (R&D System), IL-2 (Proleukin, Chiron
Corporation), mouse F(ab) anti-human IgA/M/G (Jackson
Immunoresearch) and CpG 2006 (Invivogen). NK cells were
cocultured with IMDM + 10% Human Serum and stimulated
with IL-2 (Proleukin, Chiron Corporation). T cells were cocul-
tured in RPMI + 10% Human Serum and stimulated by using
mitogenic anti-CD3 [0.5 mg/ml] and anti-CD28 [0.5 mg/ml]
mAbs (Sanquin, Pelicluster).
In the experiments with inhibitors of MSC immune modulatory
pathways [32], the following molecules were added after T cell
activation: indoleamine-2,3-dioxygenase-1 (IDO) inhibitor (L-1-
methyl-tryptophan, L-1MT - Sigma Aldrich) [1 mM]; inhibitor of
heme-oxigenase 1 (snPP - Frontier Scientific) [2 mM]; inhibitor of
COX2, an inducible enzyme involved in the production of
prostaglandin (PG)-E2 (NS398 - Cayman) [5 mM]; inhibitor of
inducible nitric oxide synthase - iNOS (L-NMMA - Cayman)
[1 mM]; IFN-gamma blocking antibody (BD Phanrmingen)
[10 mg/ml].
To assess epithelial differentiation, hMSCs from bone marrow
and lung at passage P4 were cultured for 4 weeks with DMEM
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(Gibco) + Retinoic Acid (Sigma) 10 mM. At the end of culture, cells
were either used still adherent for in situ immunofluorescence or
trypsinized and washed with PBS for the assays on cell suspension.
Other methods were tested, such as RA in combination with other
factors (EGF, epidermal growth factor; IGF - insulin growth
factor; HGF - hepatocyte growth factor; FGF10 - fibroblast growth
factor 10), as well as the addition of supernatant from immortal-
ized epithelial cell lines (16hbe human bronchial epithelial cell
line; A549 human carcinoma - alveolar basal epithelial cell line).
For quantitative reverse transcription polymerase chain reaction
(qRT-PCR), total RNA was isolated from cells with TRIzol
Reagent (Invitrogen) and retrotranscribed with High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems), according
to user’s manuals; qRT-PCR was carried out in 10 ml total volume
containing 5 ng of cDNA and 400 nM of each primer in 1x Power
SYBR Green I Master Mix (Applied Biosystems). After a starting
denaturation for 10 minutes at 95uC, 40 PCR cycles (15s 95uC
and 1 min 60uC) were performed by ABI PRISM 7900HT SDS
instrument (Applied Biosystems). Oligonucletide primers used in
qRT-PCR are listed in Table 1. Each sample was evaluated in
triplicate; specificity of PCR products was checked at the end of
each run by melting curve analysis. The probe signal was
normalized to the internal reference, and a cycle threshold was
taken above the background fluorescence. Relative quantification
of gene expression was calculated by using ACTB level as
endogenous reference. Expression data were analyzed by the
comparative method, as shown in User Bulletin #2 (Applied
Biosystems). Immortalized, human bronchial epithelial cell line
(16hbe) was used as internal control for epithelial markers.
For tissue immunofluorescence, fresh lung tissue was washed
with sterile PBS, fixed in paraformaldehyde at room temperature
for 2 hours and, after three washes with PBS, dehydrated in 30%
sucrose overnight at 4uC. After complete de-hydration, the tissue
was gradually frozen and embedded in tissue freezing medium
(OCT). Sections (8 mm) were cut by a cryostat (Leica CM1850)
and stored at 220uC. For immunofluorescent staining, sections
were incubated with blocking solution containing 5% FBS
(GIBCO) + 0.2% Triton X-100 (Sigma) in PBS for 1 hour at
RT. Incubation with uncoupled primary antibodies was carried
out overnight at 4uC; the secondary antibodies, diluted in blocking
solution, were incubated for 2 hours at RT. After wash in PBS,
samples were stained with topro3 (1:3,000) (Sigma) for 10 minutes
and mounted with the anti-bleaching reagent DABCO (Invitro-
gen). The following uncoupled anti-human primary antibodies
were used: polyclonal rabbit anti-human NG2 (Millipore),
monoclonal mouse anti-human-Nestin (R&D), monoclonal mouse
anti-human CD31 (DAKO), monoclonal mouse anti-human
CD146 (Novocastra). Secondary Cy3-labelled goat anti-mouse
and 488-donkey anti-rabbit mAbs were also used (Jackson
Immunoresearch). Nuclei were stained with Topro3 (Invitrogen,
1:3,000).
For in situ cell immunofluorescence, hMSCs at P4 were seeded
on sterile glass-culture chambers (Nunc). At the end of epithelial
differentiation protocol, culture medium was removed and cells
were fixed in PBS + 4% paraformaldehyde + 4% sucrose. Samples
were washed in PBS, incubated 30 minutes in blocking solution
(PBS + BSA 1% + Triton X-100 0.2%) and then 90 minutes with
primary antibody in blocking solution at RT. After 3 washes in
blocking solution, samples were incubated 60 minutes with
secondary antibody in blocking solution at RT. If required,
samples were treated with Zenon Mouse IgG1 Labeling Kits
(Invitrogen) to reveal secondary mouse anti-human mAbs in
double immunofluorescence, in accordance with Supplier’s
Table 1. Oligonucleotides used for quantitative RT-PCR (qRT-PCR).
Oligonucleotide (59-39) PCR product
NES, Nestin F- GCG GTGGCTCCAAGACTTC
R- ACTGGGAGCAAAGATCCAAGAC
100 bp
SMAD4, SMAD family member 4 F- TTCTGGAGGAGATCGCTTTTG
R- TTGCCTATGTGCAACCTTGCT
86 bp
NANOG, Nanog homeobox F- GCAATGGTGTGACGCAGAAG
R- AGGTTCCCAGTCGGGTTCA
94 bp
POU5F1, POU class 5 homeobox 1 F- ACCCACACTGCAGATCA
R- CCACACTCGGACCACATCCT
70 bp
SOX2, SRY (sex determining region Y)-box 2 F- CCGTTCATCGACGAGGCTAA
R- TCATGAGCGTCTTGGTTTTCC
97 bp
TDGF1, teratocarcinoma-derived growth factor 1 F- AGAACCTGCTGCCTGAATGG
R- AGTTCTCTTTGCGCACATCGT
106 bp
OCLN, occludin F- CCTATAAATCCACGCCGGTTC
R- AACGAGGCTGCCTGAAGTCA
81 bp
KRT18P19, cytokeratin 18 F- TGGAGAAGAAGGGACCCCA
R- TTGCGAAGATCTGAGACCTC
81 bp
TJP1, tight junction protein 1 F- CATCAGATCATTCTGGTCGATCA
R- TCCGGAGACTGCCATTGC
132 bp
VIM, vimentin F- TCCAAGTTTGCTGACCTCTCTG
R- CAGTGGACTCCTGCTTTGCC
76 bp
SNAI1, snail homolog 1 (Drosophila) F- TGCATATTCGGACCCACACA
R- TGTTGCAGGAGGGCAAGAA
132 bp
ACTB, actin beta F- CGCGAGAAGATGACCCAGAT
R- GTCACCGGAGTCCATCACG
125 bp
Legend: F: forward; R: reverse; bp: base pairs.
doi:10.1371/journal.pone.0035639.t001
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with topro3 (1:3,000) (Sigma) for 10 minutes and mounted with
the anti-bleaching DABCO reagent (Invitrogen). The following
antibodies were used:
– mouse anti-human Cytokeratin 18 (Pierce), mouse anti-human
E-cadherin (Dako), mouse anti-human Smooth Muscle Actin
(Dako; M0851), and mouse anti-human Occludin (Santa Cruz;
sc-81812) mAbs.
– Goat anti-mouse Alexa Fluor 546-conjugated secondary
antibody (Molecular Probes A11032, batch 419360, 1:1,000).
Images were acquired with Zeiss LSM 510 confocal microscope
equipped with argon (488 nm) and helium/neon (543 nm)
excitation lasers. For 488 nm excitation, emission was selected at
510–530 nm bandpass filter, whereas for 546 nm excitation
emission was selected by using a 560 nm longpass filter.
For polyacrylamide gel electrophoresis and western blotting,
cellular proteins were harvested by using deoxycholate (DOC) and
quantified by using a BCA protein assay (Pierce). Equal amounts
of proteins were loaded on 10% polyacrylamide gel and
transferred to a nitrocellulose membrane. After blocking with
3% milk in Tris-Buffered Saline + Tween 0.1% (TBS-T),
membranes were incubated with primary antibodies overnight
and stained with anti-mouse IgG horseradish peroxidase-conju-
gated antibodies (Sigma) for 1 hour. Protein levels were detected
by chemio-luminescence (Pierce). Monoclonal mouse anti-human
Cytokeratin 18 (Pierce) and monoclonal mouse anti-human
Vimentin (Dako) mAbs were used as primary antibodies. Beta-
actin was used as marker of protein loading (monoclonal mouse
anti-human beta actin - Sigma).
Tight junction integrity in BM-hMSCs and lung-hMSCs was
assessed during epithelial differentiation by measuring the
transepithelial electrical resistance (TEER) with an EVOM
epithelial voltmeter (World Precision Instruments, Sarasota, FL,
USA). 5610
5 cells were seeded on TranswellH filter inserts (Cell
Culture Insert 0.4 mm, Falcon) in 24 multi-well plates (Falcon).
TEER measurement on hMSCs was performed 3 times a week
during the 4 weeks of epithelial differentiation. The apical volume
in the TranswellH system was 200 ml and the basal volume in the
multi-well was 700 ml. Data were normalized in V6cm
2. The
background of the filter inserts (4565 V6cm
2) was subtracted
from other measures.
Statistical Analysis
Data were expressed as mean 6 standard deviation (SD).
Differences among the experimental conditions were analyzed by
using non-parametrical tests (Wilcoxon and Kruskal-Wallis with
Dunns post test for multiple comparisons). P value ,0.05 was
considered statistically significant.
Results
Isolation and Characterization of Lung-hMSCs
Cell suspensions obtained after disaggregation of fresh human
lung samples and plated in culture medium gave rise after 7–
10 days to multiple colonies of plastic-adherent fibroblast-like cell
colonies with the same morphological features of CFU-F obtained
with BM-hMSCs (Figure 1A). Adherent cells were enzymatically
disaggregated and re-plated; within 2–5 passages from the initial
plating of the primary culture, lung-derived adherent cells
displayed the typical spindle-shaped, fibroblastic morphology of
BM-MSCs (Figure 1A). These cells showed high proliferative rate,
with an average population doubling time of 34.6613.0 hours
(data not shown).
Immunophenotyping for surface antigens was performed by
flow cytometry on lung-derived adherent cells and BM-hMSCs at
passages 2–7 (Table 2). Lung-derived cells, as well as BM-hMSCs,
were negative for hematopoietic, endothelial and monocyte
markers (CD45, CD31, CD34, CD117, CD14) and costimulatory
molecules (CD80, CD86). In addition, both cell types expressed
markers of mesenchymal progenitors (CD44, CD73, CD90,
CD105 and CD106) and perivascular cells (CD146 and NG2),
and resulted positive for HLA class I (Table 2).
The expression at mRNA level of a panel of stemness-related
genes was evaluated by qRT-PCR in lung-derived adherent cells
Figure 1. Characterization of lung-hMSCs. (A) Morphology of lung-hMSCs. Inverted phase-contrast microscopy of primary colonies of lung-
hMSCs (left panel) and expanded colonies at confluence (right panel). (B)( left panel) Characterization by qRT-PCR of stemness profile of cells extracted
from lung tissues (dark grey columns) in comparison with BM-hMSCs (ligh grey columns). Relative gene expression fold induction of nestin (nes),
smad4, nanog, pou5f1(or Oct4), sox2 and tdgf1 (or Cripto). Gene expression is normalized on actb gene (beta actin) and related to BM-hMSCs as basal
expression. Mean 6 SD; *=p,0.01; (B)( right panel) Analysis of nestin expression detected by flow cytometry in lung-hMSCs (dark grey column) and
BM-hMSCs (light grey column). Columns show Nestin fluorescence ratio normalized on the fluorescence of the relative isotype. Mean 6 SD. * p,0.01.
(C) Schematic representation of clonogenic and self-renewal assays with a representative case of a single colony obtained from CFU-F assay,
consisting of more than 50 cells. Scale bar: 1 mm. (D) Multilineage differentiation potential. Lung-hMSCs, under appropriate stimuli, can generate
adipocytes (left panel), osteocytes (middle panel) and chondrocytes (right panel), as confirmed by the staining with Oil-red-O, alkaline phosphatase
(ALP) and Tolouidin Blue dyes, respectively.
doi:10.1371/journal.pone.0035639.g001
Table 2. Characterization of BM-hMSCs and lung-hMSCs by
flow cytometry. Data are expressed as marker/isotype
fluorescence ratio (n=6).
BM-hMSC lung-hMSC
CD45 160.03 160.08
CD31 160.1 160.03
CD34 160.03 160.07
CD14 160.08 160.03
CD80 160.1 160.2
CD86 160.06 160.08
CD44 173682 14163.8
CD73 44627 55612
CD90 3966111 3866178
CD105 765.1 3,861.2
CD106 8165.7 1.660.1
CD117 160.04 160.06
CD146 1668 6.564.2
NG2 10611 1 61.6
HLA-I 41632 4 61.2
HLA-II 160.1 160.2
doi:10.1371/journal.pone.0035639.t002
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NANOG, POU5F1 (also named oct4), SOX2 and TDGF1 (also
named cripto) was not significantly different in the two cell
populations; by contrast, NES (Nestin-coding gene) expression
resulted 21 times-higher in lung-derived adherent cells (P,0.01)
(Figure 1B). Cytofluorimetric analysis of Nestin protein, normal-
ized on the relative isotype, confirmed the higher expression of
Nestin in the cells obtained from lung tissues (P,0.01) (Figure 1B).
CFU-F assay performed with cells derived from lung tissue and
BM-hMSCs led to similar results (19.461.2% and 20.162.0%,
respectively, n=6). In addition, self-renewal capacity of adherent
cells derived from lung tissue was demonstrated by dissociating
and replating primary colonies that gave rise to secondary colonies
similarly to BM-MSCs (Figure 1C). Finally, the ability to
differentiate into multiple mesodermal lineages, i.e. adipocytes,
osteocytes and chondrocytes, was similar in the two cell
populations (Figure 1D). According to all these results, these cells
could be properly named lung-hMSCs.
Activated T cells were cocultured with lung-hMSCs for 6 days,
as described in Materials and Methods. Similarly to BM-hMSCs,
lung-hMSCs displayed their inhibitory effect on T cell prolifera-
tion at 1:10 MSC/T cell ratio, whereas at 1:100 ratio no effect was
observed. The differences in the inhibitory effect between the two
hMSC types were not statistically significant (Figure 2A, left panel).
Figure 2. Immune regulatory properties. (A) Effect of the coculture of MSCs derived from human BM (light grey) and human lung (dark grey) on
the proliferation of B, NK and T cells. Different MSC:Effector ratios were assessed as shown in the legend. Means6SD. * p,0.01, ** p,0.03. (B)
Molecular mechanisms underlying the immune regulatory properties of BM-hMSCs (light grey) and lung-hMSCs (dark grey) towards T cells.
Proliferation of T cells was evaluated without MSCs or at 10:1 ratio with hMSCs from BM and lung, in presence of specific inhibitors of known
pathways: IDO-inhibitor L-1-methyl-tryptophan (L-1MT), inhibitor of heme-oxigenase 1 (snPP), COX2 -inhibitor (NS398), iNos-inhibitor (L-NMMA) and
IFN-gamma blocking antibody.
doi:10.1371/journal.pone.0035639.g002
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found by coculture assays with activated NK cells for 5 days: both
hMSC types exerted the maximum inhibitory effect on NK cell
proliferation at 1:1 MSC/NK cell ratio, whereas no significant
effect was observed at 1:10 ratio (Figure 2A, middle panel).
Coculture of lung-hMSCs with B cells showed that lung-hMSCs
and BM-hMSCs have similar supportive effect towards B cells. In
fact, B cell proliferation was enhanced by the coculture with either
lung-hMSCs or BM-hMSCs. No significant differences were
observed in the enhancement of B cell proliferation mediated by
both hMSC types (Figure 2A, right panel).
The molecular mechanism underlying the immune regulatory
effect of hMSCs on T cell proliferation was also investigated by
using specific inhibitors [17]. IDO resulted the pivotal mechanism
involved in hMSC immunomodulation, as the addition of its
specific inhibitor L-1MT completely reverted the modulatory
effect (Figure 2B). In addition, heme-oxigenase 1 (inhibited by
snPP) and IFN-c (inhibited by specific blocking antibodies)
resulted partially involved in the regulatory effect of hMSCs,
although in a non-statistically significant manner; by contrast, no
effect was observed by using COX2 inhibitor to block PGE2
production (NS398) and iNOS inhibitor (L-NMMA) (Figure 2B).
Immunofluorescence on lung sections was performed by using
anti-NG2, -CD146, -CD31 and -Nestin antibodies to identify in
situ lung-hMSC niches; the co-expression of NG2 and CD146 was
used to detect lung-hMSCs. Double-positive cells were found
surrounding endothelial cells (CD31-positive cells) at perivascular
level; in addition, NG2-positive cells co-expressed Nestin protein
(Figure 3), thus confirming the results obtained by qRT-PCR and
FACS analysis performed on cultured cells.
Epithelial Differentiation Potential of Lung-hMSCs
Only modest results could be obtained in absence of RA, i.e. the
partial upregulation of the cytokeratin 18 at lower levels than with
RA. On the other hand, the addition of FGF10 to RA did not
enhance significantly epithelial differentiation. Similarly, superna-
tant from either 16hbe or a549 immortalized epithelial cell lines
induced the upregulation of specific epithelial markers but not
organized MET (data not shown). Thus, to assess whether lung-
hMSCs possess some tissue-specific properties, we focused our
attention on the effects of RA on lung-hMSCs and BM-hMSCs.
Both MSC types were cultured for 4 weeks with RA, as described
in Materials and Methods, and the effect of RA on hMSCs was
analyzed at phase-contrast microscopy. As shown in Figure 4A,
both lung-hMSCs and BM-hMSCs acquired at the end of culture
a round-cuboid shape resembling a monolayer of epithelial cells,
but these features were more remarkable in lung-hMSCs. Cells
maintained the typical mesenchymal shape in the controls
(untreated MSCs from lung and BM) (Figure 4A). The expression
of three epithelial genes (cytokeratin 18, occludin and tight-
junction protein) and two mesenchymal genes (vimentin and
snai1), known to be involved in the epithelial-mesenchymal
transition [7,8], were evaluated by qRT-PCR in MSCs cultured
in presence of RA. Untreated lung-hMSCs showed higher basal
expression of the three epithelial transcripts, as compared to
untreated BM-hMSCs (Figure 4B). After RA treatment, both
hMSC types upregulated the epithelial genes, which anyway
reached the highest levels of expression in RA-treated lung-
hMSCs (Figure 4B). Of the mesenchymal genes analyzed, both
vimentin and snai1 transcripts were more highly expressed at basal
level in untreated BM-hMSCs rather than in lung-hMSCs.
Following RA treatment, vimentin expression was significantly
down-regulated in both BM-hMSCs and lung-hMSCs (Figure 4B),
but snai1 expression declined only in lung-hMSCs (Figure 4B).
The expression of vimentin and cytokeratin 18 proteins was
analyzed by western blotting on protein extracts to confirm the
differences demonstrated at transcriptional level (Figure 4C).
Lung-hMSCs always displayed lower expression of vimentin
protein before and after RA treatment in comparison to BM-
hMSCs (Figure 4C). The expression of the bronchial epithelial
protein cytokeratin 18 was detectable only in lung-hMSCs after
RA treatment (Figure 4C).
Further characterization of induced epithelial differentiation of
lung-hMSCs was carried out by immunofluorescence. This
method showed that a small percentage of lung-hMSCs after
RA treatment displayed signs of epithelial differentiation, as
confirmed by the double-positive staining for cytokeratin 18 and
occludin (Figure 4D), the reduction of SMA protein and the
expression of E-cadherin (Ecad) (Figure 4D).
At this point it was important to assess whether these molecular
changes were associated to the acquisition of specific functional
properties, typical of epithelial cells. To this aim, lung-hMSCs
were analyzed by Trans Epithelial Electric Resistance (TEER)
assay after RA treatment to assess and quantify the formation of
tight and adherence junctions among vital cells. As shown in
Figure 4E, after RA treatment both BM-hMSCs and lung-hMSCs
acquired partial epithelial polarization, typical of ‘‘leaky epithelia’’
(TEER,200 V6cm
2). Full epithelial polarization, specific for
Figure 3. In vivo localization of lung-hMSCs at perivascular level. Immunofluorescence on human lung tissue sample with anti-NG2 and anti-
CD31 (left panel), anti-NG2 and anti-CD146 (middle panel), and anti-NG2 and anti-Nestin (right panel) mAbs. White arrows: cells of interest. Nuclei are
stained with Topro3 in blue.
doi:10.1371/journal.pone.0035639.g003
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2), was never observed.
However, lung-hMSCs resulted more prone to polarization (mean
TEER=60 V 6cm
2) if compared to BM-hMSCs (mean
TEER=40 V6cm
2).
Discussion
In this study, a population of lung-hMSCs were identified,
isolated, expanded and characterized as far as morphology,
growth kinetics, immunophenotype, stemness-related gene expres-
Figure 4. Epithelial differentiation. (A) Morphology changes after epithelial differentiation. Inverted phase-contrast microscopy (Zeiss
Observer.Z1; 100x) of BM-hMSCs and lung-hMSCs without and with RA treatment (Ctrl; +RA). (B) Evaluation of epithelial differentiation by qRT-PCR on
BM-hMSCs (light grey) and lung-hMSCs (dark grey), before (basal) and after RA treatment for the induction of epithelial differentiation. Panel shows
the expression of the epithelial genes cytokeratin 18 (krt18), tight junction protein (tjp1), also named zona occludens 1, occludin (ocln) and
mesenchymal genes vimentin (vim) and e-cadherin repressor snai1. Data are normalized on actb (beta actin) expression and related to basal BM-
hMSCs. The error bars represent standard deviation; *= p,0.01; **=p,0.03; ***=p,0.05. (C) Evaluation of epithelial differentiation by Western Blot
with anti-vimentin (left panel) and anti-cytokeratin 18 (right panel) antibodies on protein extract of BM-hMSCs (lane 1-2) and lung-hMSCs (lane 3–4),
either untreated (Ctrl) or treated with RA (+RA). (D) Evaluation by immunofluorescence of epithelial differentiation of lung-hMSCs after RA treatment.
Staining with anti-cytokeratin 18 (CK18) and Occludin (OCLN) (left panel), and with E-cadherin (Ecad) and anti-smooth muscle actin (SMA) (right panel)
mAbs. Nuclei are stained with Topro3 in blue. (E) Functional evaluation of epithelial differentiation with Trans-Epithelial Electric Resistance (TEER).
Histograms show the value of TEER (V*cm
2) on BM-hMSCs (light grey) and lung-hMSCs (dark grey), before and after RA treatment. The error bars
represent standard deviation; **=p,0.03; ***=p,0.05.
doi:10.1371/journal.pone.0035639.g004
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towards T, B and NK cells are concerned. Altogether, our data
show close similarities between lung-hMSCs and BM-MSCs, but
also some tissue-specific peculiarities in terms of expression of
Nestin and epithelial markers (cytokeratin 18, occludin and tight-
junction protein), which confirm the distinct nature of these cells
from BM-hMSCs [33,34]. Lung-hMSC could be identified in vivo
at perivascular level in the bronchioalveolar region of the lung, as
cells co-expressing NG2, CD146 and Nestin and negative for
endothelial markers, such as CD31, and CD117 (c-kit). The role of
Nestin in lung-hMSCs is unknown. Nestin is an intermediate
filament protein that was originally suggested as marker for
embryonic and adult stem/progenitor cells of the central nervous
system [35]; however, it has been described also in non-neural
stem cell populations [36]. Our data are in agreement with
previous reports showing the presence of Nestin-positive stem cells
with multilineage differentiation capability and mesenchymal
phenotype in some epithelial microenvironments, i.e pancreatic
gland epithelium [37]. Thus, lung-hMSCs seem to be different
from the epithelial stem cells recently described in the lung (c-kit-
positive) [38]; lung-hMSCs are more closely related to the MSC
progenitors widely diffuse in multiple human organs [11] and
obtainable from fetal lung tissues [13] and bronchioalveolar lavage
(BAL) from lung-transplanted recipients [14]. Similarly to BM-
hMSCs, lung-hMSCs are capable of supporting B cell growth and
down-regulating T and NK cell proliferation. The inhibition of T
cell proliferation mainly depends on IDO activity; other pathways
resulted only partially (heme-oxigenase 1 and IFN-c) or not
involved (COX-2/PGE2 and iNOS) in the regulatory effect of
lung-hMSCs. PGE2 has been recently suggested as the main
soluble factor released by lung-resident MSCs affecting T cell
activity [39]. However, the cells described in that paper were not
obtained from normal lung tissues, but from BAL of immuno-
compromized lung-transplanted patients; in addition, the effect of
IDO on T cell proliferation was not assessed; thus, the inhibitory
machinery of those lung-derived MSCs could have been
influenced by the pathological microenviroment [39].
It is known from literature that tissue origin of MSCs may drive
their differentiation properties [12]; however, the comparison of
hMSCs of different origin, as far as epithelial differentiation is
concerned, is still lacking. Our data show that lung-hMSCs after
RA treatment can undergo a MET-like process more easily than
BM-hMSCs, as shown by the significant up-regulation of three
important epithelial genes (cytokeratin 18, occludin and tight-
junction protein), together with the down-regulation of the
mesenchymal genes vimentin and snai1 (the e-cadherin repressor),
whose expression was significantly lower in lung-hMSCs even at
basal level. Epithelial commitment was detectable both at protein
level, as assessed by Western Blotting and immunofluorescence
assays, and at functional level, as confirmed by TEER assay; the
latter showed the ability of lung-hMSCs to acquire higher degree
of polarization than BM-hMSCs during epithelial differentiation in
vitro. Thus, lung-hMSCs seem to be constitutively more prone to
epithelial differentiation than BM-hMSCs. Accordingly, the higher
expression of Nestin transcript and protein by lung-hMSCs could
reflect their greater plasticity towards different polarizing signals.
Nevertheless, epithelial differentiation reached in vitro by lung-
hMSCs was partial, as shown by the abnormal localization of the
Ecad (typical of the transition state), the weak functional
polarization (TEER,200 V6cm
2), and the slight increase of
specific lung epithelial transcripts, such as cystic fibrosis trans-
membrane conductance regulator protein (cftr) and surfactant
proteins (data not shown). These results may reflect either the
heterogeneity of MSC population or the inadequacy of the stimuli
used for MET induction. However, RA was the strongest in vitro
epithelial differentiation-inducing stimulus in our hands, as the
addition of other factors, such as EGF, IGF, HGF or FGF10 did
not significantly change the effects obtained with RA alone (data
not shown). We also tried to induce epithelial differentiation of
hMSCs by using the supernatant obtained from immortalized lung
epithelial cell lines (16hbe or A549); however, this approach led
only to the upregulation of some specific epithelial markers rather
than to organized MET (data not shown). These results are in
agreement with several papers pointing out the essential role of RA
in lung development [16–21,23,25], and as molecular inducer of
cell differentiation [26–28] and postnatal recovery factor
[22,29,30]. Nevertheless, the in vivo contribution of retinoids to
the activation and induction of the epithelial differentiation of
lung-hMSCs needs to be preliminarily assessed in in vivo models of
lung regeneration following tissue damage, before speculating
about any possible usefulness of lung-hMSCs in pulmonary
regenerative medicine.
By contrast, lung-hMSC characterization here described may
be useful to study a variety of lung diseases, such as chronic
obstructive pulmonary disease (COPD) and idiopathic pulmonary
fibrosis (IPF). In fact, both diseases are characterized by abnormal
remodelling of alveolar spaces (emphysema and bronchiolitis in
COPD, irreversible fibrosis in IPF), which is probably associated to
the severe impairment of the cross-talk between the two
pulmonary stem cell compartments (alveolar epithelial precursors
and mesenchymal progenitors), together with a poorly character-
ized dysregulation of the local immunity [40–45]. Alveolar
epithelial stem cells (type II pneumocytes) are mainly affected in
IPF [46–48], whereas most damages affect mesenchymal precur-
sor cells within the alveolar parenchyma in COPD [49–51].
Abnormal senescence of mesenchymal precursors in emphysema
leads to parenchyma loss, defective production of extracellular
matrix proteins, such as elastin and fibronectin, and progressive
weakening of the alveolar structures [49–55]. In addition, it is
likely that the immune regulatory properties of lung mesenchymal
precursors are affected in COPD pathogenesis, as abnormal
immunological and inflammatory reactions have been described in
this disease [40,55–57]. Thus, the availability of normal lung-
hMSCs may represent a good model in vitro to assess at
immunophenotypic, molecular, and functional levels the patho-
logical changes occurring in COPD and IPF, and to study the
reciprocal interactions between epithelial stem cells and MSCs of
pulmonary origin in normal and pathological conditions.
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